Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(12):839-841; doi:10.1093/jnci/95.12.839
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Welch, D. R.
Right arrow Articles by Hunter, K. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welch, D. R.
Right arrow Articles by Hunter, K. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 12, 839-841, June 18, 2003
© 2003 Oxford University Press

EDITORIAL

A New Member of the Growing Family of Metastasis Suppressors Identified in Prostate Cancer

Danny R. Welch, Kent W. Hunter

Affiliations of authors: D. R. Welch, Department of Pathology and Comprehensive Cancer Center, The University of Alabama at Birmingham; K. W. Hunter, Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD.

Correspondence to: Danny R. Welch, Ph.D., Department of Pathology, The University of Alabama at Birmingham, 1670 University Blvd., Volker Hall G-038, Birmingham, AL 35294–0019 (e-mail: dwelch@path.uab.edu).

The first 150 words of the full text of this article appear below.

The molecular understanding of cancer metastasis has taken yet another step forward with findings published in this issue of the Journal by Fu et al. (1). The authors report that restoration of Raf kinase inhibitor protein (RKIP) expression is associated with the inhibition of prostate carcinoma metastasis but not with the suppression of tumorigenicity. In addition, the authors report an inverse association between RKIP expression and both the stage of disease and Gleason score. These properties epitomize metastasis suppressor genes, a recently described category of molecules defined by their ability to suppress metastasis without blocking tumorigenicity (2). RKIP is the thirteenth metastasis suppressor described in the literature for which functional data exist (the others are Nm23, KISS1, KAI1, BRMS1, TIMPs, E-cadherin, MKK4, TXNIP, CRSP3, DRG-1, SSeCKs, and RhoGDI2). Several recent reviews summarize what is known regarding the mechanisms of action of metastasis suppressors and the clinical . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
Z. Kovacevic and D. R. Richardson
The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer
Carcinogenesis, December 1, 2006; 27(12): 2355 - 2366.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. Zhang, H. Yamashita, T. Toyama, Y. Yamamoto, T. Kawasoe, and H. Iwase
Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
Clin. Cancer Res., November 1, 2006; 12(21): 6410 - 6414.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. S Perry, R. Foley, K. Woodson, and M. Lawler
The emerging roles of DNA methylation in the clinical management of prostate cancer.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Theodorescu, L. M. Sapinoso, M. R. Conaway, G. Oxford, G. M. Hampton, and H. F. Frierson Jr.
Reduced Expression of Metastasis Suppressor RhoGDI2 Is Associated with Decreased Survival for Patients with Bladder Cancer
Clin. Cancer Res., June 1, 2004; 10(11): 3800 - 3806.
[Abstract] [Full Text] [PDF]